RxDoctor Payments Data

Ann Rogerson, NP

Nurse Practitioner · Provo, UTNPI 1770953317

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,239 of the $4,369 with a category attached, or 74.1%. 20 manufacturers reported payments, led by Abbott at 33.3% of the total. Among nurse practitioner clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,369in general payments, 2019–2025

Across 198 payments — averaging $22.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Novartis$406
  • Boston Scientific$365
  • Boehringer Ingelheim$335
  • Actelion Pharmaceuticals US, Inc.$282
  • E.r. Squibb & Sons, L.L.C.$282
  • plus $1K from 14 others

What the payments were for

  • Travel & lodging$1,08625%
  • Food & beverage$3,23974%
  • Education$431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,369 in reported general payments places this provider in the 90th percentile of 979 nurse practitioner providers in Utah.

See all nurse practitioner providers in Utah

Medicare billing

Part B allowed, 2024
$25,225
Medicare patients
108
Services billed
291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban85$98,051
JardianceEmpagliflozin97$95,318
EntrestoSacubitril/Valsartan30$30,113
FarxigaDapagliflozin Propanediol26$21,346
XareltoRivaroxaban20$17,390
Metoprolol Succinate188$2,542
Atorvastatin Calcium141$1,677
Ranolazine ErRanolazine15$1,218
Carvedilol63$1,174
Losartan Potassium86$1,129
Spironolactone121$1,089
ClopidogrelClopidogrel Bisulfate54$895
Potassium Chloride46$764
Furosemide142$745
Isosorbide Mononitrate ErIsosorbide Mononitrate46$601

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$246$98,05185 claims
Boehringer IngelheimJardiance$335$95,31897 claims
NovartisEntresto$406$30,11330 claims
Johnson & JohnsonXarelto$275$17,39020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 979 nurse practitioner providers in Utah.

Other nurse practitioner in Provo

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →